Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

Vaccine

Volumn 29, Issue 44, 2011, Pages 7826-7834

  López Macías, Constantino ^a   Ferat Osorio, Eduardo ^a   Tenorio Calvo, Alejandra ^a,b   Isibasi, Armando ^a   Talavera, Juan ^a   Arteaga Ruiz, Oscar ^a   Arriaga Pizano, Lourdes ^c   Hickman, Somia P ^c   Allende, María ^c   Lenhard, Kathy ^c   Pincus, Steven ^c   Connolly, Kevin ^c   Raghunandan, Ramadevi ^c   Smith, Gale ^c   Glenn, Gregory ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c NOVAVAX INC   (United States)

Author keywords

H1N1; HAI; Influenza vaccine; Pandemic influenza; Virus like particle; VLP

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTHRALGIA; ARTICLE; BODY TEMPERATURE; CAPILLARY RESISTANCE; CHEST TIGHTNESS; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEMAGGLUTINATION INHIBITION TEST; HOARSENESS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; LEPIDOPTERA; MALE; MEXICO; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SKIN REDNESS; SKIN SWELLING; SORE THROAT; VOMITING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELL LINE; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MEXICO; MIDDLE AGED; PLACEBOS; SPODOPTERA; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIROSOME; YOUNG ADULT;

EID: 80053606312     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.099     Document Type: Article

References (30)

1. (PCAST) PsCoAoSaT. Plan to improve Nation's vaccine response against pandemic influenza and other outbreaks. In: Policy OoSaT, Washington, DC, 2010.
2. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23(50):5751-5759.
3. Safdar A., Cox M.M. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Invest Drugs 2007, 16(July (7)):927-934.
4. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25(21):4283-4290.
5. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
6. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(42):5393-5399.
7. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83(11):5726-5734.
8. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(30):4771-4776.
9. Liu Y.V., Massare M.J., Barnard D.L., Kort T., Nathan M., Wang L., Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glyoprotein and influenza matrix 1 effciently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 2011, Jul 14 [Epub ahead of print]. 10.1016/j.vaccine.2011.06.111.
10. Raghunandan R., Massare M., Smith G., Connolly K. Safety and efficacy of a novel RSV F-particle vaccine candidate in two preclinical RSV challenge models. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010.
11. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447):1757-1765.
12. Cohen J., Enserink M. Swine flu. After delays WHO agrees: the 2009 pandemic has begun. Science 2009, 324(5934):1496-1497.
13. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58(RR-10):1-8.
14. Girard M.P., Katz J., Pervikov Y., Palkonyay L., Kieny M.P. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva Switzerland, 17-18 February 2010. Vaccine 2010, 28(42):6811-6820.
15. Wu J., Xu F., Lu L., Lu M., Miao L., Gao T., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010, 363(25):2416-2423.
16. Boletín Epidemiología; 2010; Available from: [cited 2011 19-04-11]. http://www.dgepi.salud.gob.mx/boletin/boletin.htm.
17. MedDRA® Term Selection, Version 12.1. Application to adverse drugs reactions/adverse events & medical and social history & indications. Geneva: ICH; 2009.
18. Carrat F., Pelat C., Levy-Bruhl D., Bonmarin I., Lapidus N. Planning for the next influenza H1N1 season: a modelling study. BMC Infect Dis 2010, 10:301.
19. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
20. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010, 28(31):4895-4902.
21. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
22. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(9708):56-66.
23. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
24. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
25. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
26. Lu C.Y., Shao P.L., Chang L.Y., Huang Y.C., Chiu C.H., Hsieh Y.C., et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 2010, 28(36):5864-5870.
27. Kao T.M., Hsieh S.M., Kung H.C., Lee Y.C., Huang K.C., Huang L.M., et al. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 2010, 28(38):6159-6163.
28. Valenciano M., Kissling E., Cohen J.M., Oroszi B., Barret A.S., Rizzo C., et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011, 8(1):e1000388.
29. Van Buynder P.G., Carcione D., Rettura V., Daly A., Woods E. Marketing paediatric influenza vaccination: results of a major metropolitan trial. Influenza Other Respir Viruses 2011, 5(1):33-38.
30. Andrews N., Waight P., Yung C.F., Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011, 203(1):32-39.